13F Holdings
中文EN

APYX Apyx Medical Corp

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 719135 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY24.4%
TTM net income YoY42.0%
TTM EPS YoY—
Revenue 3-yr CAGR5.8%
Net income 3-yr CAGR—

Margins

Gross margin63.4%
Operating margin-5.5%
Net margin-14.2%
FCF margin-14.9%
EBITDA margin-4.1%

Returns

ROE-109.0%
ROA-14.2%
ROIC (approx.)-14.9%
Asset turnover1.00x

Leverage & solvency

Liabilities / assets83.7%
Debt / equity3.69x
Current ratio4.95x
Interest coverage-0.59x

Cash quality & payout

Operating cash flow / net income0.98x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$52.84M$48.10M$52.35M$44.51M$48.52M
Cost of revenue$19.80M$18.74M$18.59M$15.38M$14.92M
Gross profit$33.04M$29.36M$33.76M$29.13M$33.60M
R&D expense$3.37M$5.08M$5.44M$4.54M$4.32M
SG&A expense$15.80M$18.86M$22.20M$20.48M$18.62M
Operating income-$6.45M-$18.84M-$17.26M-$23.56M-$14.45M
Interest expense$5.59M$5.91M$2.48M$15,000$10,000
Pretax income-$10.84M-$23.31M-$21.28M-$22.91M-$14.82M
Income tax$270,000$252,000-$2.43M$367,000$380,000
Net income-$11.21M-$23.46M-$18.71M-$23.18M-$15.17M
EBITDA-$5.79M-$18.25M-$16.57M-$22.67M-$13.54M
EPS (basic)-0.27-0.66-0.54-0.67-0.44
EPS (diluted)——-0.54-0.67-0.44
Weighted avg. shares (diluted)——34.62M34.52M34.33M
Balance sheet
Cash & equivalents$31.74M$31.74M$43.65M$10.19M$30.87M
Receivables$16.78M$15.48M$14.02M$10.60M$13.04M
Inventory$8.60M$7.56M$9.92M$11.80M$6.78M
Current assets$58.47M$56.44M$70.36M$42.97M$60.74M
PP&E, net$2.37M$1.99M$1.92M$6.76M$6.58M
Total assets$66.84M$64.84M$79.24M$51.77M$68.72M
Current liabilities$11.70M$10.72M$12.74M$11.85M$13.21M
Short-term debt———$0—
Long-term debt$34.85M$33.89M$33.19M$0—
Total debt$34.85M$33.89M$33.19M$0—
Total liabilities$52.01M$50.51M$52.32M$13.98M$14.71M
Shareholders' equity$14.54M$14.21M$26.70M$37.58M$53.70M
Net debt$3.11M$2.15M-$10.47M-$10.19M—
Shares outstanding41.79M37.79M34.64M34.60M34.41M
Cash flow statement
Operating cash flow-$8.00M-$18.05M-$5.25M-$20.28M-$10.45M
Capital expenditure$1.11M$722,000$533,000$1.01M$723,000
Free cash flow-$9.12M-$18.77M-$5.78M-$21.29M-$11.17M
Investing cash flow-$1.11M-$722,000$6.73M-$1.01M-$723,000
Financing cash flow$9.58M$6.75M$32.17M$217,000$24,000
Depreciation & amortization$655,000$599,000$692,000$890,000$903,000
Stock-based compensation$2.00M$4.01M$5.11M$6.70M$5.09M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.